Brendon Neuen's Publications

About Brendon Neuen's Publications

Senior Research Fellow, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

    Circulation Date published:

  • Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

    Kidney International Reports Date published:

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Kidney International Reports Date published:

  • Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

    Diabetes Care Date published:

  • Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial

    International Journal of Cardiology Date published:

  • Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet Date published:

  • Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

    Cardiovascular Diabetology Date published:

  • Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations

    Current Hypertension Reports Date published:

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Journal of the American Society of Nephrology Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

    Journal of the American Society of Nephrology Date published:

  • The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

    Diabetes, Obesity and Metabolism Date published:

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published:

  • Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

    Kidney International Date published:

  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine Date published: